© 2023 NOVAVAX. All rights reserved. 1 This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including information relating to the future of Novavax, its key strategic priorities and commercial goals, its operating plan ...

Novavax, Inc. (NASDAQ:NVAX) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Erika Schultz - Senior Director of IR John Jacob - President and CEO John Trizzino - EVP and Chief Commercial Officer Filip Dubovsky - Chief Medical Officer James Kelly - EVP and CFO Rick Crowley - COO Conference Call Participants Roger Song - Jefferies Alec Stranahan - Bank of America Merrill Lynch Georgi Yordanov - Cowen and Company Eric Joseph - JPMorgan Mayank Mamtani - B. Riley Securities FBR ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of Registrant as specified in its charter) Delaware 22-2816046 (State of incorporation) (I.R.S. ...

Novavax, Inc. (NASDAQ:NVAX) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Silvia Taylor - Executive Vice President & Chief Communications Officer Stan Erck - President & Chief Executive Officer Filip Dubovsky - Chief Medical Officer John Trizzino - Chief Commercial Officer & Chief Business Officer Jim Kelly - Chief Financial Officer & Treasurer Conference Call Participants Roger Song - Jefferies Georgi Yordanov - Cowen and Company Mayank Mamtani - B. Riley Securities Alec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Commission File No. 000-26770 NOVAVAX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 21 Firstfield Road Gaithersburg MD 20878 (Address of principal executive offices) (Zip code) (240) 268-2000 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whethe ...

Novavax, Inc. (NASDAQ:NVAX) Baird 2022 Global Healthcare Conference Call September 13, 2022 8:30 AM ET Company Participants Gregory Glenn - President, R&D John Trizzino - Chief Commercial Officer and Chief Business Officer Unidentified Analyst Hey, good morning, everyone and welcome to Baird???s Annual Healthcare Conference. I am really pleased to be kicking off the conference with Novavax. And with me today, I have Gregory Glenn, President of R&D; and John Trizzino, Chief Commercial Officer and Chief Busin ...

Novavax, Inc. (NASDAQ:NVAX) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 4:00 PM ET Company Participants Gregory Glenn - Chief Scientific Officer John Trizzino - Chief Business Officer and Chief Commercial Officer Conference Call Participants Vernon Bernardino - H.C. Wainwright Vernon Bernardino Hi, everyone. Thanks for coming to the H.C. Wainwright Global Healthcare Conference. My name is Vernon Bernardino. I'm a senior analyst at H.C. Wainwright., covering Novavax. From No ...

Novavax, Inc. (NASDAQ:NVAX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Silvia Taylor - SVP, Global Corporate Affairs and Investor Relations Stan Erck - President and Chief Executive Officer Filip Dubovsky - Chief Medical Officer John Trizzino - Chief Commercial Officer and Chief Business Officer Jim Kelly - Chief Financial Officer and Treasurer Greg Glenn - President-Research and Development Conference Call Participants Georgi Yordanov - Cowen and Co Roger Song - Jefferi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26770 NOVAVAX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

vaccines today FIRST QUARTER 2022 FINANCIAL RESULTS & OPERATIONAL HIGHLIGHTS NASDAQ: NVAX | MAY 9TH, 2022 © 2022 NOVAVAX. All rights reserved. 1 SAFE HARBOR STATEMENT Certain information, particularly information relating to the future of Novavax, its key strategic priorities for 2022, its 2022 financial guidance, its operating plans, objectives and prospects, its partnerships, its future financial or business performance, conditions, or strategy, including expectations regarding revenue, product demand, op ...